9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea
Seoul National University Hospital
Jeongha Mok; Myungsun Lee; Deog Kyeom Kim; Ju Sang Kim; Byung Woo Jhun; Kyung-Wook Jo; Doosoo Jeon; Taehoon Lee; Ji Yeon Lee; Jae Seuk Park; Seung Heon Lee; Young Ae Kang; Jung-Kyu Lee; Nakwon Kwak; Joong Hyun Ahn; Tae Sun Shim; Song Yee Kim; Seungmo Kim; Kyungjong Kim; Kwang-Hyuk Seok; Soyeong Yoon; Young Ran Kim; Jisu Kim; Dahae Yim; Seokyung Hahn; Sang Nae Cho; Jae-Joon Yim; MDR-END investigators